{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:59:10Z","timestamp":1784631550870,"version":"3.55.0"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"04","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>68Ga-PSMA-HBED-CC (68Ga-PSMA-11) was approved by the U.S. Food and Drug Administration as the first prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging drug for patients with prostate cancer. However, the utility of 68Ga-PSMA-HBED-CC may be limited due to PET\/CT or PET\/MR accessibility and 68GaCl3 availability produced from 68Ge\/68Ga generator or cyclotron. Thus, in-house preparation of 99mTc-PSMA-HBED-CC was developed as an alternative to 68Ga-PSMA-HBED-CC to be ubiquitous and affordable in the worldwide population.<\/jats:p>\n                  <jats:p>A solution of 99mTc-pertechnetate was added to PSMA-HBED-CC and 4% SnCl2\u00b72H2O in a 10-mL sterile vial. The mixture was heated at 100\u00b0C for 15\u2009minutes and then allowed to cool to room temperature. Labeling conditions were optimized to maximize the radiochemical yield of 99mTc-PSMA-HBED-CC. The chelation completeness was monitored using instant thin layer chromatography, and the stability of 99mTc-PSMA-HBED-CC was subsequently evaluated.<\/jats:p>\n                  <jats:p>The radiolabeling of 99mTc-PSMA-HBED-CC was successful using the appropriate amount of 10 \u00b5g PSMA-HBED-CC 3 \u00b5g SnCl2\u00b72H2O and 99mTc-pertechnetate 370 MBq at 100\u00b0C for 15\u2009minutes, yielded the best result in high radiochemical yield (71.49\u2009\u00b1\u20092.42%), radiochemical purity (98.29\u2009\u00b1\u20092.65%), and specific activity of 37.84\u2009\u00b1\u20091.47 GBq\/\u00b5mol. 99mTc-PSMA-HBED-CC is stable with radiochemical purity of more than 95% within 4\u2009hours at room temperature.<\/jats:p>\n                  <jats:p>A new labeling method of 99mTc-PSMA-HBED-CC was developed. Quality control parameters of 99mTc-PSMA-HBED-CC met the criteria in accordance with the European Pharmacopoeia.<\/jats:p>","DOI":"10.1055\/s-0045-1809921","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T18:55:52Z","timestamp":1750964152000},"page":"319-324","source":"Crossref","is-referenced-by-count":1,"title":["A New Labeling Method of 99mTc-PSMA-HBED-CC"],"prefix":"10.1055","volume":"24","author":[{"given":"Benchamat","family":"Phromphao","sequence":"additional","affiliation":[{"name":"Medical Physics Program, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"},{"name":"Chulalongkorn University Biomedical Imaging Group, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4560-0803","authenticated-orcid":false,"given":"Shuichi","family":"Shiratori","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"06","key":"ref1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.21037\/tau.2019.09.37","article-title":"Transrectal ultrasound biopsy of the prostate: does it still have a role in prostate cancer diagnosis?","volume":"9","author":"A Moe","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/ph14080713","article-title":"[68Ga] Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer","volume":"14","author":"U Hennrich","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","article-title":"[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH","volume":"39","author":"A Afshar-Oromieh","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"01","key":"ref5","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"D A Silver","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"17","key":"ref6","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1073\/pnas.0502101102","article-title":"Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase","volume":"102","author":"M I Davis","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1107\/S090744490700902X","article-title":"Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA","volume":"63","author":"J R Mesters","year":"2007","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/pharmaceutics14051098","article-title":"Design, synthesis, and evaluation of linker-optimised PSMA-targeting radioligands","volume":"14","author":"F Lundmark","year":"2022","journal-title":"Pharmaceutics"},{"issue":"24","key":"ref9","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1021\/jm800765e","article-title":"Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization","volume":"51","author":"C Barinka","year":"2008","journal-title":"J Med Chem"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA-PET in prostate cancer management","volume":"13","author":"T Maurer","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00259-017-3882-2","article-title":"Current status of theranostics in prostate cancer","volume":"45","author":"I Virgolini","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3390\/biomedicines10102533","article-title":"The performance of FDA-approved PET imaging agents in the detection of prostate cancer","volume":"10","author":"M Li","year":"2022","journal-title":"Biomedicines"},{"issue":"15","key":"ref13","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1021\/jm800111u","article-title":"Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA)","volume":"51","author":"S R Banerjee","year":"2008","journal-title":"J Med Chem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ica.2012.03.002","article-title":"Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: effects of chelate design on pharmacokinetics","volume":"389","author":"K P Maresca","year":"2012","journal-title":"Inorg Chim Acta"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.bmcl.2012.09.014","article-title":"Synthesis and SAR of 99mTc\/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates","volume":"23","author":"G Lu","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2967\/jnumed.116.178939","article-title":"Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer","volume":"58","author":"S Robu","year":"2017","journal-title":"J Nucl Med"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2967\/jnumed.112.116624","article-title":"99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer","volume":"54","author":"S M Hillier","year":"2013","journal-title":"J Nucl Med"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2967\/jnumed.114.140426","article-title":"99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer","volume":"55","author":"S Vallabhajosula","year":"2014","journal-title":"J Nucl Med"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RLU.0000000000001433","article-title":"First experience with SPECT\/CT using a 99mTc-labeled inhibitor for prostate-specific membrane antigen in patients with biochemical recurrence of prostate cancer","volume":"42","author":"J Reinfelder","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s12149-019-01400-6","article-title":"PSMA SPECT\/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels","volume":"33","author":"C Schmidkonz","year":"2019","journal-title":"Ann Nucl Med"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1038\/s41598-020-61129-5","article-title":"Evaluation of radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer","volume":"10","author":"J Zhang","year":"2020","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nucmedbio.2017.01.010","article-title":"99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen","volume":"48","author":"X Xu","year":"2017","journal-title":"Nucl Med Biol"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1021\/mp9000712","article-title":"Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents","volume":"6","author":"S A Kularatne","year":"2009","journal-title":"Mol Pharm"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5603\/NMR.2021.0018","article-title":"SPECT-CT imaging with [99mTc] PSMA-T4 in patients with recurrent prostate cancer","volume":"24","author":"S Sergieva","year":"2021","journal-title":"Nucl Med Rev"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"191247","DOI":"10.1098\/rsos.191247","article-title":"Synthesis of novel technetium-99m tricarbonyl-HBED-CC complexes and structural prediction in solution by density functional theory calculation","volume":"6","author":"S Shi","year":"2019","journal-title":"R Soc Open Sci"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1039\/C9MD00401G","article-title":"Preparation and clinical translation of 99mTc-PSMA-11 for SPECT imaging of prostate cancer","volume":"10","author":"K Vats","year":"2019","journal-title":"Med Chem Commun"},{"key":"ref27","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"J S Horoszewicz","year":"1987","journal-title":"Anticancer Res"},{"issue":"19","key":"ref28","first-page":"6423","article-title":"Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5","volume":"50","author":"A D Lopes","year":"1990","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0022-5347(17)32453-9","article-title":"Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence","volume":"152","author":"D Kahn","year":"1994","journal-title":"J Urol"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pros.2990180305","article-title":"Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356)","volume":"18","author":"G E Wynant","year":"1991","journal-title":"Prostate"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","article-title":"68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging","volume":"23","author":"M Eder","year":"2012","journal-title":"Bioconjug Chem"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1809921.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T23:52:19Z","timestamp":1767743539000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1809921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":31,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2026,1,6]]},"published-print":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0045-1809921","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}